Human parathyroid hormone (1–34) and (1–84) increase the mechanical strength and thickness of cortical bone in rats

An anabolic effect on bone of intermittent parathyroid hormone (PTH) treatment has been found in patients with osteoporosis and also in experimental animals. Controversies exist, however, about whether the positive effect on the trabecular bone balance occurs at the expense of the cortical bone. We examined the biomechanical quality of cortical bone after intermittent treatment with different doses of PTH and, furthermore, compared the effects of PTH‐(1–34) and PTH‐(1–84). Groups of rats were treated with biosynthetic human PTH‐(1–34) or PTH‐(1–84), 1.1, 3.3, 10, or 30 nmol/kg/day for 30 days. No changes in the body weights and no changes in the lengths of the femora were observed after the PTH treatments. The bio‐mechanical properties were analyzed by means of a materials‐testing machine. A dose‐related increase in the bending strength and stiffness of the femora was found, and this increase in mechanical strength corresponds with a 9–12% increase in the cross‐sectional area of the femoral diaphyses. The deflection capability and energy absorption were not influenced by any of the PTH treatments. No differences were found between the effects of PTH‐(1–34) or PTH‐(1–84) on the biomechanical properties of the femora. Consequently, intermittent treatment with biosynthetic PTH‐(1–34) or PTH‐(1–84) increased the formation of cortical bone, and the biomechanical competence of the femora was found to be preserved.

[1]  J. Hock,et al.  Human parathyroid hormone-(1-34) increases bone mass in ovariectomized and orchidectomized rats. , 1988, Endocrinology.

[2]  D. Kalu,et al.  Human parathyroid hormone‐(1‐34) prevents bone loss and augments bone formation in sexually mature ovariectomized rats , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  R. Ziegler,et al.  Stimulation of bone matrix apposition in vitro by local growth factors: a comparison between insulin-like growth factor I, platelet-derived growth factor, and transforming growth factor beta. , 1990, Endocrinology.

[4]  William M. O'Fallon,et al.  Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. , 1990 .

[5]  E. Canalis,et al.  Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. , 1989, The Journal of clinical investigation.

[6]  J. Hock,et al.  Loss of the anabolic effect of parathyroid hormone on bone after discontinuation of hormone in rats. , 1989, Bone.

[7]  O. Tørring,et al.  Parathyroid hormone and parathyroid hormone-related peptide stimulate insulin-like growth factor-binding protein secretion by rat osteoblast-like cells through a adenosine 3',5'-monophosphate-dependent mechanism. , 1991, Endocrinology.

[8]  J. Heersche,et al.  Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. , 1982, Endocrinology.

[9]  R. Boyce,et al.  Resorption is not essential for the stimulation of bone growth by hPTH‐(1‐34) in rats in vivo , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  T. Andreassen,et al.  The stimulating effect of growth hormone on fracture healing is dependent on onset and duration of administration. , 1991, Clinical orthopaedics and related research.

[11]  E. Canalis,et al.  Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone. , 1989, Endocrinology.

[12]  O. Tørring,et al.  The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84). , 1991, Endocrinology.

[13]  R M Neer,et al.  Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1–34) and 1,25‐dihydroxyvitamin D , 1986, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  A. Lindahl,et al.  Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. , 1987, Endocrine reviews.

[15]  J Reeve,et al.  Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. , 1980, British medical journal.

[16]  T. Andreassen,et al.  Mechanical properties and biochemical composition of rat cortical femur and tibia after long-term treatment with biosynthetic human growth hormone. , 1991, Bone.

[17]  J. Reeve,et al.  Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride. , 1990, BMJ.

[18]  J. Hock,et al.  Anabolic effect of human synthetic parathyroid hormone-(1-34) depends on growth hormone. , 1990, Endocrinology.

[19]  J. Pennock,et al.  Parathyroid hormone and experimental osteosclerosis. , 1970, Lancet.

[20]  J. V. van Leeuwen,et al.  A two-receptor model for the action of parathyroid hormone on osteoblasts: a role for intracellular free calcium and cAMP. , 1985, Cell calcium.